Armata Pharmaceuticals, Inc. (ARMP)
USD 1.87
(-6.5%)
USD 1.87
(-6.5%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 82.3 Million USD | 158.79% |
| 2022 | 31.8 Million USD | -12.82% |
| 2021 | 36.48 Million USD | 235.39% |
| 2020 | 10.87 Million USD | 599.49% |
| 2019 | 1.55 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 570 Thousand USD | -93.03% |
| 2005 | 8.17 Million USD | -19.69% |
| 2004 | 10.18 Million USD | -9.31% |
| 2003 | 11.22 Million USD | -45.22% |
| 2002 | 20.49 Million USD | 24.94% |
| 2001 | 16.4 Million USD | 570.58% |
| 2000 | 2.44 Million USD | 16.48% |
| 1999 | 2.1 Million USD | 133.33% |
| 1998 | 900 Thousand USD | -40.0% |
| 1997 | 1.5 Million USD | -28.57% |
| 1996 | 2.1 Million USD | -12.5% |
| 1995 | 2.4 Million USD | 4.35% |
| 1994 | 2.3 Million USD | 130.0% |
| 1993 | 1 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 28.15 Million USD | -100.0% |
| 2024 Q1 | 35.36 Million USD | -57.03% |
| 2023 Q4 | 82.3 Million USD | -17.85% |
| 2023 FY | 82.3 Million USD | 158.79% |
| 2023 Q2 | 27.43 Million USD | -13.85% |
| 2023 Q3 | 100.18 Million USD | 265.24% |
| 2023 Q1 | 31.84 Million USD | 0.11% |
| 2022 Q4 | 31.8 Million USD | -14.56% |
| 2022 Q2 | 37.23 Million USD | 0.84% |
| 2022 FY | 31.8 Million USD | -12.82% |
| 2022 Q1 | 36.92 Million USD | 1.21% |
| 2022 Q3 | 37.22 Million USD | -0.03% |
| 2021 Q3 | 10.58 Million USD | -0.91% |
| 2021 FY | 36.48 Million USD | 235.39% |
| 2021 Q2 | 10.68 Million USD | -0.86% |
| 2021 Q1 | 10.77 Million USD | -0.94% |
| 2021 Q4 | 36.48 Million USD | 244.64% |
| 2020 Q4 | 10.87 Million USD | -0.29% |
| 2020 Q2 | 11.53 Million USD | 872.93% |
| 2020 Q3 | 10.9 Million USD | -5.46% |
| 2020 Q1 | 1.18 Million USD | -23.73% |
| 2020 FY | 10.87 Million USD | 599.49% |
| 2019 Q4 | 1.55 Million USD | -18.16% |
| 2019 Q3 | 1.9 Million USD | -21.26% |
| 2019 Q2 | 2.41 Million USD | 0.0% |
| 2019 Q1 | - USD | 0.0% |
| 2019 FY | 1.55 Million USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2007 Q1 | 569 Thousand USD | -0.18% |
| 2007 FY | - USD | -100.0% |
| 2007 Q2 | 454 Thousand USD | -20.21% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q3 | - USD | -100.0% |
| 2006 FY | 570 Thousand USD | -93.03% |
| 2006 Q1 | 8.16 Million USD | -0.2% |
| 2006 Q2 | 8.15 Million USD | -0.06% |
| 2006 Q4 | 570 Thousand USD | -88.6% |
| 2006 Q3 | 5 Million USD | -38.67% |
| 2005 Q4 | 8.17 Million USD | -0.24% |
| 2005 FY | 8.17 Million USD | -19.69% |
| 2005 Q3 | 8.19 Million USD | -18.61% |
| 2005 Q1 | 10.12 Million USD | -0.54% |
| 2005 Q2 | 10.07 Million USD | -0.55% |
| 2004 Q1 | 11.03 Million USD | -1.71% |
| 2004 Q2 | 10.87 Million USD | -1.47% |
| 2004 Q3 | 10.23 Million USD | -5.87% |
| 2004 Q4 | 10.18 Million USD | -0.52% |
| 2004 FY | 10.18 Million USD | -9.31% |
| 2003 Q1 | 20.48 Million USD | -0.05% |
| 2003 Q4 | 11.22 Million USD | -0.99% |
| 2003 Q2 | 20.53 Million USD | 0.25% |
| 2003 Q3 | 11.33 Million USD | -44.78% |
| 2003 FY | 11.22 Million USD | -45.22% |
| 2002 Q1 | 16.89 Million USD | 2.98% |
| 2002 FY | 20.49 Million USD | 24.94% |
| 2002 Q2 | 21.87 Million USD | 29.48% |
| 2002 Q4 | 20.49 Million USD | -9.04% |
| 2002 Q3 | 22.53 Million USD | 3.02% |
| 2001 Q1 | 2.32 Million USD | -4.94% |
| 2001 Q4 | 16.4 Million USD | 40.63% |
| 2001 Q3 | 11.66 Million USD | 202.39% |
| 2001 Q2 | 3.85 Million USD | 65.88% |
| 2001 FY | 16.4 Million USD | 570.58% |
| 2000 Q2 | 2.32 Million USD | 8.11% |
| 2000 Q3 | 2.64 Million USD | 13.75% |
| 2000 Q4 | 2.44 Million USD | -7.35% |
| 2000 FY | 2.44 Million USD | 16.48% |
| 2000 Q1 | 2.14 Million USD | 2.23% |
| 1999 Q2 | 1.3 Million USD | 30.0% |
| 1999 FY | 2.1 Million USD | 133.33% |
| 1999 Q4 | 2.1 Million USD | 90.91% |
| 1999 Q1 | 1 Million USD | 11.11% |
| 1999 Q3 | 1.1 Million USD | -15.38% |
| 1998 Q1 | 1.6 Million USD | 6.67% |
| 1998 Q2 | 1.4 Million USD | -12.5% |
| 1998 Q3 | 1.2 Million USD | -14.29% |
| 1998 Q4 | 900 Thousand USD | -25.0% |
| 1998 FY | 900 Thousand USD | -40.0% |
| 1997 FY | 1.5 Million USD | -28.57% |
| 1997 Q1 | 2 Million USD | -4.76% |
| 1997 Q2 | 2 Million USD | 0.0% |
| 1997 Q3 | 1.8 Million USD | -10.0% |
| 1997 Q4 | 1.5 Million USD | -16.67% |
| 1996 Q1 | 2.6 Million USD | 8.33% |
| 1996 FY | 2.1 Million USD | -12.5% |
| 1996 Q4 | 2.1 Million USD | -4.55% |
| 1996 Q2 | 2.4 Million USD | -7.69% |
| 1996 Q3 | 2.2 Million USD | -8.33% |
| 1995 Q4 | 2.4 Million USD | 20.0% |
| 1995 FY | 2.4 Million USD | 4.35% |
| 1995 Q3 | 2 Million USD | -9.09% |
| 1995 Q1 | 2.3 Million USD | 0.0% |
| 1995 Q2 | 2.2 Million USD | -4.35% |
| 1994 FY | 2.3 Million USD | 130.0% |
| 1994 Q4 | 2.3 Million USD | 35.29% |
| 1994 Q2 | 1.8 Million USD | 0.0% |
| 1994 Q3 | 1.7 Million USD | -5.56% |
| 1993 FY | 1 Million USD | 0.0% |
| 1993 Q4 | 1 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | -16527.677% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Actinium Pharmaceuticals, Inc. | 1.57 Million USD | -5135.814% |
| Azitra, Inc. | 563.69 Thousand USD | -14501.414% |
| Can-Fite BioPharma Ltd. | 13 Thousand USD | -633030.769% |
| Chromocell Therapeutics Corporation | - USD | -Infinity% |
| Calidi Biotherapeutics, Inc. | 2.06 Million USD | -3895.485% |
| CEL-SCI Corporation | 11.6 Million USD | -609.389% |
| iBio, Inc. | 3.5 Million USD | -2246.935% |
| Lineage Cell Therapeutics, Inc. | 2.07 Million USD | -3876.184% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 2.89 Million USD | -2743.074% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | -4297.411% |
| NovaBay Pharmaceuticals, Inc. | 1.1 Million USD | -7328.43% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | - USD | -Infinity% |
| BiomX Inc. | 5.4 Million USD | -1423.639% |
| BiomX Inc. | 5.4 Million USD | -1423.639% |
| Protalix BioTherapeutics, Inc. | 4.62 Million USD | -1681.151% |
| Palatin Technologies, Inc. | 163.78 Thousand USD | -50153.996% |
| Scorpius Holdings, Inc. | 12.61 Million USD | -552.549% |